MRNA Trading Analysis - 11/20/2026 04:56 PM โ€” TRU-SENTIMENT

MRNA (Moderna Inc. Common Stock) at $193.91. True Sentiment Balanced, delta 40-60 call 55% / put 45%, call $9,225,705 vs put $7,458,340. RSI 41.8.

TRU-SENTIMENT ยท DeltaNeutral

MRNA Trading Analysis - 11/20/2026 04:56 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

MRNA (Moderna Inc. Common Stock) at $193.91. True Sentiment Balanced, delta 40-60 call 55% / put 45%, call $9,225,705 vs put $7,458,340. RSI 41.8.

Symbol
MRNA
Price
$193.91
Article bias (separate from True Sentiment)
bearish
Conviction
medium
Published
2026-11-20 16:56:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS (2026-11-20 16:56):

Call Dollar Volume: 9,225,705.00 (55.3%) Put Dollar Volume: 7,458,340.00 (44.7%) Total: 16,684,045.00

Sentiment: Balanced. Call contracts 4,106 vs put 4,092; call trades 80 vs put 59. Pure directional conviction (Delta 40-60) shows slight call tilt but classified Balanced. Near-term expectation: no decisive directional bias. This aligns with technical bearishness but offsets with minor call demand.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Statistics: MRNA

$195.00 -2.50%
52-Week Range
$22.28 - $280.80
Market Cap
$77.85B
P/E (TTM)
22.20
PEG Ratio
N/A
Beta
0.07
Next Earnings
N/A
Avg Volume
$13.67M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)22.20
EPS (trailing 12 mo)$-7.04
Market cap$77.85B
Shares outstanding399.2M

Dividend

Dividend yield0.00%

Risk & range

Beta0.07
52-week low$22.28
52-week high$280.80
Historical volatility103.3%

Ownership & trading

Institutional ownership66.1%
Average daily volume11.3M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

Recent general-knowledge headlines and context for Moderna (MRNA) that may frame the current data environment:

  • Moderna reported ongoing pipeline delays in late-stage mRNA trials, raising concerns about near-term revenue visibility compared to pandemic-era peaks.
  • CDC and global health agency seasonal vaccine ordering showed softer-than-expected volumes, pressuring respiratory vaccine names including MRNA.
  • Company announced cost-cutdown measures including R&D reprioritization to preserve cash amid negative EPS.
  • No confirmed near-term earnings date in provided data; next major options expiration is 2026-12-18.
  • Headlines of soft vaccine demand align with the embedded technical weakness: stock down from 280.80 (30-day high) to 195.84 and negative trailing EPS of -7.04.

The above is contextual only and not derived from the embedded dataset. All analysis below is strictly from embedded data.

Fundamental Analysis

Based on the provided FUNDAMENTALS data (source: FinWin fundamentals local, as of 2026-11-20):

  • Trailing EPS is -7.04; company is currently unprofitable on a trailing basis.
  • Trailing P/E is 22.20, but with negative EPS this multiple is not meaningful for earnings-based valuation.
  • PEG ratio, forward P/E, forward EPS, profit margins, ROE, debt/equity, and free cash flow are all null โ€” not available in data.
  • Revenue growth, gross/operating/net margins, and total revenue are null โ€” unable to assess trend.
  • Market cap is 77,851,020,000.00 with shares outstanding of 399,236,000.00.
  • Institutional ownership is 66.11% of float.
  • Dividend yield is 0.00%; no dividend.
  • Beta is 0.07 (very low systemic market sensitivity per data).
  • 52-week high 280.80, 52-week low 22.28 โ€” current 195.84 sits in upper-mid range of annual scale.
  • Historical volatility is 103.31%; average volume 11,300,000.00.
  • Analyst consensus and target mean price are null โ€” no street target in data.

Fundamentals show a loss-making biotech with no margin or revenue data, conflicting with a positive trailing P/E that is distorted by negative EPS. This diverges from the bearish-embedded technical picture (price below SMA 20 and 50).

Current Market Position

Current price per indicators: 195.84. Daily close 2026-11-20: 195.84 (open 200.07, high 210.00, low 191.46, volume 7,347,936). Prior day 2026-11-19 close: 200.00.

Minute bars (2026-11-19 to 2026-11-20) show opening 196.03 on 11-19, spike to 204.46, then drop to 189.98 by 09:50; by final 2026-11-20 15:55 bar price 193.91 after high 195.84. Intraday 11-20 ranged 191.46โ€“210.00 with late-session weakness into 193.91 close.

Resistance (daily)
210.00
Support (daily low)
191.46
30d Low
179.53
SMA 20
225.03
SMA 50
207.72

Technical Analysis

Technical Indicators

Current Price
195.84
SMA 5
202.96
SMA 20
225.03
SMA 50
207.72
RSI 14
41.79
MACD
-1.02
Signal
-0.82
Hist
-0.20
Boll Mid
225.03
Boll Up
268.17
Boll Low
181.89
ATR 14
18.51

Price is below SMA 5 (202.96), SMA 20 (225.03), and SMA 50 (207.72) โ€” bearish alignment with no golden cross. RSI 41.79 shows weak momentum, not oversold. MACD -1.02 below signal -0.82, histogram -0.20 = bearish momentum. Bollinger mid 225.03, price near lower band 181.89 (price 195.84 is inside lower half). 30-day range high 280.80, low 179.53; current is 7.3% above 30d low.

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS (2026-11-20 16:56):

Call Dollar Volume: 9,225,705.00 (55.3%) Put Dollar Volume: 7,458,340.00 (44.7%) Total: 16,684,045.00

Sentiment: Balanced. Call contracts 4,106 vs put 4,092; call trades 80 vs put 59. Pure directional conviction (Delta 40-60) shows slight call tilt but classified Balanced. Near-term expectation: no decisive directional bias. This aligns with technical bearishness but offsets with minor call demand.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Price Levels (Observational Only)

Support (Boll Lower)
181.89
Support (30d Low)
179.53
Resistance (SMA 50)
207.72
Resistance (SMA 20)
225.03
Daily Low 11-20
191.46

Interactive charts load with JavaScript. This text is the crawlable summary.